Evidence map›Paper›PMID 39528654›Full record

ArticleThe EMBO journal2024

METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma.

Ketan Thombare, Roshan Vaid, Perla Pucci, Kristina Ihrmark Lundberg, Ritish Ayyalusamy, Mohammad Hassan Baig, Akram Mendez, Rebeca Burgos-Panadero, Stefanie Höppner, Christoph Bartenhagen and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. NAR cancer · 2026
    Article
  2. The expanding role of mAdvanced biotechnology · 2026
    Review
  3. Review
  4. Epigenetic crosstalk in neuroblastoma development and progression.Frontiers in cell and developmental biology · 2026
    Review
  5. Molecular regulation and therapeutic targeting ofFrontiers in cell and developmental biology · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ketan Thombare *Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0002-0183-3376
Roshan Vaid *Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0002-2074-5080
Perla Pucci *Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-1264-3487
Kristina Ihrmark LundbergChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institute, and Pediatric Oncology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0009-0003-7099-0644
Ritish AyyalusamyDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0009-0003-8081-9357
Mohammad Hassan BaigDepartment of Family Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, 211 Eonju-Ro, Gangnam-Gu, Seoul, 06273, Republic of Korea.ORCID http://orcid.org/0000-0001-8227-4838
Akram MendezDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Rebeca Burgos-PanaderoDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0003-0811-2675
Stefanie HöppnerDepartment of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, Cologne, Germany.
Christoph BartenhagenDepartment of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, Cologne, Germany.
Daniel SjövallSahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, SE-40530, Gothenburg, Sweden.
Aqsa Ali RehanDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0009-0008-9030-7992
Sagar Dattatraya NaleBNJ Biopharma, Memorial Hall, 85, Songdogwahak-ro, Yeonsu-gu, Incheon, 21983, Republic of Korea.
Anna DjosDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Tommy MartinssonDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Pekka JaakoSahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, SE-40530, Gothenburg, Sweden.ORCID http://orcid.org/0000-0003-3587-8318
Jae-June DongDepartment of Family Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, 211 Eonju-Ro, Gangnam-Gu, Seoul, 06273, Republic of Korea.
Per KognerChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institute, and Pediatric Oncology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
John Inge JohnsenChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institute, and Pediatric Oncology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-1277-812X
Matthias FischerDepartment of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, Cologne, Germany.ORCID http://orcid.org/0000-0003-1363-1242
Suzanne D TurnerDivision of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.
Tanmoy MondalDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden. tanmoy.mondal@gu.se.ORCID http://orcid.org/0000-0001-6228-8001

Funding

Barncancerfonden (Swedish Childhood Cancer Foundation) PR2019-0077Barncancerfonden (Swedish Childhood Cancer Foundation) PR2023-0079Barncancerfonden (Swedish Childhood Cancer Foundation) TJ2019-0077Cancerfonden (Swedish Cancer Society) 22-2341Cancerfonden (Swedish Cancer Society) 230753PTVetenskapsrådet (VR) 2018- 02224
6 · The paper itself

Abstract

Neuroblastoma (NB) is the most common extracranial childhood cancer, caused by the improper differentiation of developing trunk neural crest cells (tNCC) in the sympathetic nervous system. The N

Indexed as

Cell DifferentiationMethyltransferasesNeural CrestNeuroblastomaN-Myc Proto-Oncogene ProteinAdenosineAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceAdenosineMethyltransferasesMETTL3 protein, humanMYCN protein, humanN-methyladenosineN-Myc Proto-Oncogene ProteinHOX Genesm6AMETTL3MYCNNeuroblastoma

Identifiers

PMID39528654
PMCPMC11649786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.